Caris Life Sciences Inc. Common Stock (CAI)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Caris with Graham's caution and Buffett's demand for evidence. The business—molecular profiling and AI/ML for cancer—has real growth: filed revenue rose from $306.1M in fiscal 2023 to $412.3M in fiscal 2024 and $812.0M in fiscal 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $263.7M versus $181.4M in fiscal Q2 2025, and net loss narrowed to $0.637M from $71.8M. That is operating leverage, and trailing-twelve-month free cash flow of $124.0M is a positive sign. But a moat is not proven by rapid sales alone; I see no evidence in these figures of durable pricing power. The company still lost $68.1M in fiscal 2025 and has losses in each of the last three years, so the computed Lynch category is none. Financial health is decent: debt-to-equity is 0.76, FairStock Altman Z-Score is 6.74, and Piotroski F-Score is 6/9. But FairStock P/B is 15.53 and EV/EBITDA is 50.99. At the $32.46 close on 2026-10-26, the FairStock Graham Number of $21.22 implies a -50.80% margin of safety, FCF yield is only 1.4%, and the FairStock score is 27/100. The FairStock P/E of 3.39 looks too good against filed diluted EPS of -$3.22 in fiscal 2025 and $0.00 in fiscal Q2 2026; I discount it. Growth is impressive, but the price already assumes success.

In plain English: Caris Life Sciences sells molecular testing and AI tools that help doctors understand cancer. Sales are growing fast and losses are getting much smaller, but the company has not yet made a full-year profit. At $32.46, the stock looks expensive compared with its asset value and a conservative estimate of what the business is worth, and it is near its 52-week high.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer